Papillary microcarcinoma and papillary cancer of the thyroid ≤1 cm: Modified definition of the WHO and the therapeutic dilemma

NuklearMedizin

Volumn 46, Issue 4, 2007, Pages 115-120

  Schönberger, Johann ^a   Marienhagen, J ^a   Agha, A ^a   Rozeboom, S ^a   Bachmeier, E ^a   Schlitt, H ^a   Eilles, C ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Papillary microcarcinoma; Thyroid cancer; Thyroid surgery; Treatment guidelines

Indexed keywords

IODINE 131;

AGE DISTRIBUTION; AGED; BONE METASTASIS; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER SIZE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PAPILLARY CARCINOMA; REVIEW; SEX DIFFERENCE; THYROID CANCER; THYROID PAPILLARY MICROCARCINOMA; WHOLE BODY SCINTISCANNING; WORLD HEALTH ORGANIZATION;

HUMANS; IODINE RADIOISOTOPES; PAPILLOMA; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 34548425032     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1160/nukmed-0059     Document Type: Review

References (36)

1. Bisi H, Fernandes VS, de Camargo RY et al. The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma. Cancer 1989; 64: 1888-1893.
2. Chow SM, Law SCK, Au SK et al. Changes in Clinical Presentation, Management and Outcome in 1348 Patients with Differentiated Thyroid Carcinoma: Experience in a Single Institute in Hong Kong, 1960-2000. Clin Oncol 2003; 15: 329-336.
3. Chow SM, Law SCK, Chan JKC et al. Papillary Microcarcinoma of the Thyroid - Prognostic Significance of Lymph Node Metastasis and Multifocality. Cancer 2003; 98: 31-40.
4. Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 1-33.
5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006; 295: 2164-2167.
6. Dietlein M, Dressler J, Farahati J et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version2). Nuklearmedizin 2004; 43: 115-120.
7. Dietlein M, Luyken WA, Schicha H et al. Incidental multifocal papillary microcarcinomas of the thyroid: Is subtotal thyroidectomy combined with radioiodine ablation enough?. Nucl Med Comm 2005; 26: 3-8.
8. Dietlein M, Schober O, Schicha H. Overtherapy or undertherapy for papillary thyroid microcarcinoma? Nuklearmedizin 2004; 43: 107-114.
9. Grebe SKG, Hay ID. The role of surgery in the management of differentiated thyroid cancer. J Endocrinol Invest 1997; 20: 32-35.
10. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 1985; 56: 531-538.
11. Hay ID, Grant CS, Bergstralh EJ et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998; 124: 958-966.
12. Hay ID, Grant CS, van Heerden JA et al. Papillary thyroid microcarcinoma: a study of 533 cases observed in a 50-year period. Surgery 1992; 112: 1139-1147.
13. nd ed. Berlin: Springer 1988.
14. Ito Y, Nakano K, Takamura Y et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13: 381-387.
15. Kjellman P, Wallin G, Hoog A et al. MIB-1 index in thyroid tumors: a predictor of the clinical course in papillary thyroid carcinoma. Thyroid 2003; 13: 371-380.
16. LiVolsi VA. Papillary carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press 2004.
17. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative Analysis. Cancer 2005; 103: 2269-2273.
18. Mazzaferri E, Young RL. Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511-518.
19. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
20. NCCN Practice Guidelines in Oncology - v. 1.2005. In version 1.2005 ed: National Comprehensive Cancer Network via internet www.nccn.org.
21. Noguchi S, Yamasha H, Murakami N et al. Small carcinomas of the thyroid. Arch Surg 1996; 131: 187-191.
22. Ommer A, Bottel P, Stremmel W. How good is the prognosis in differentiated thyroid gland carcinoma? Langenbecks Arch Surg (Suppl) 1996; 113: 192-195.
23. Pacini F, Molinaro E, Castagna MG et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 3668-3673.
24. Pacini F, Schlumberger M, Dralle H et al. and the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eu J Endocrinol 2006; 154: 787-803.
25. Passler C, Scheuba C, Asari R et al. Importance of tumour size in papillary and follicular thyroid cancer. Brit J Surg 2005; 92: 184-189.
26. Pelizzo MR, Boschin IM, Toniato A et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 2004; 25: 547-552.
27. Ringel M. Diagnostic Molecular Markers in Thyroid Cancer. In: Farid NR (ed). Molecular Basis of Thyroid Cancer. Boston/New York/Dordrecht/London: Kluwer 2004; 295-316.
28. Roti E, Rossi R, Trasforini G et al. Clinical and histological characteristics of papillary thyroid microcarcinomas: Results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006; 91: 2171-2178.
29. Sawka AM, Thephamongkhol K, Brouwers M et al. A systematical review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-dofferentited thyroid cancer. J Clin Endocrinol Metab 2004; 89: 3668-3676.
30. Schlumberger M, Pacini F, Wiersinga WM et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004; 151: 539-548.
31. Schwab R, Wieler H, Birtel S et al. Confronting the practice of surgery on differentiated thyroid cancer with current guidelines in Germany. A multicenter trial. Nuklearmedizin 2005; 44: 185-191.
32. Shattuck TM, Westra WH, Ladenson PW et al. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 2005; 352: 2406-2412.
33. Sherman SI, Brierley P, Becker HP et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National thyroid cancer treatment cooperative study registry group. Cancer 1998; 83: 1012-1021.
34. Wieler H, Bartenstein P, Becker HP et al. Guideline for the therapy of malignant thyroid tumours. Pleading for an actualization. Nuklearmedizin 2004; 43: 121-123.
35. Wittekind C, Meyer JH, Bootz F. TNM Klassifikation maligner Tumoren. Berlin: Springer 2003.
36. Yamamoto Y, Maeda T, Izumi K et al. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer 1990; 65: 1173-1179.